Archer advances as a pure-play deep tech

Good morning, in this fourth issue of Archer’s 2021 Newsletter, we report on the simplification of the Archer business through the sale of its mineral tenements and how the Company is ramping up its activities in the deep tech space.

Archer recently signed a legally binding share sale agreement for the sale of all of the subsidiary companies that hold the Company’s mineral tenements.

Upon completion of the sale, Archer will no longer hold any mineral exploration licences, mining leases or any other type of mineral tenement.

This is a significant milestone for the Company in becoming a pure-play deep tech, and more information can be found here.

The milestone simplifies Archer’s business and should help the Company to attract interest from technology focussed investors and businesses.

Archer will hold an extraordinary general meeting to seek shareholder approval of the sale and matters relating to the sale. The Company expects a notice of meeting to be distributed to Archer shareholders in June/July 2021.

As part of our growth, we continue to attract talented technologists to work on promising, potential solutions to global challenges that have significant socio-economic implications.

One of these technologies is our graphene-based biochip. As we ramp up our biochip development, we will strategically bridge industry capability gaps that add the greatest amount of value, and where possible, locally.

For example, Archer has progressed to one of the most advanced forms of nanofabrication after recently translating biosensor components onto silicon wafers.

We have recently commenced development towards a key technological milestone of achieving sub-10 nanometre biochip components. We are doing this in a world-class research and prototype semiconductor foundry in Sydney, Australia.

Sub-10 nanometres represents global best-in-class in the semiconductor industry and will help us consolidate a global competitive advantage in the multibillion-dollar point of care medical diagnostics industry.

As we solve significant technological barriers in our biochip development, the Company will rapidly translate this knowledge into strong IP assets - a hallmark of successful deep-techs - that underpins high value, long-term commercialisation, and I look forward to updating you on our exciting progress.

Sincerely,

Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX:AXE)

Read the full Newsletter here